Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07374120 · ClinicalTrials.gov registry record
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,480
- Enrollment target
NCT07374120: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07374120 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,480 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07374120 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,480 participants
- Enrollment target
Study Summary
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,480 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2025-01-21 |
What the finished NCT07374120 record still lists
NCT07374120 is an observational study that tracks outcomes without assigning an intervention. Its 1,480 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07374120 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07374120 about?
NCT07374120 is a clinical study titled "Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting". This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Pati...
What is the current status of trial NCT07374120?
This trial is currently completed. The enrollment target is 1,480 participants. The study started on 2024-02-01. Estimated completion is 2025-01-21.
Who is sponsoring clinical trial NCT07374120?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869552 · 1,485 participants · NA
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI